DexCom, Inc. (DXCM)
After hours:
| Previous Close | 131.91 |
| Open | 131.72 |
| Bid | 131.33 x 400 |
| Ask | 131.44 x 400 |
| Day's Range | 130.16 - 132.22 |
| 52 Week Range | 74.75 - 142.00 |
| Volume | |
| Avg. Volume | 2,925,872 |
| Market Cap | 52.24B |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | 85.30 |
| EPS (TTM) | 1.54 |
| Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 153.37 |
Business WireDexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
LONDON, May 20, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM device that easily tracks real-time glucose readings to help improve diabetes management, and the Dexcom State of Type 2 Report. The report is a first-of-its-kind look at the Type 2 landscape today and examines the preferences and behaviours of those living with the condition, as well as their caretaker
ZacksReasons to Retain DexCom (DXCM) Stock in Your Portfolio Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
GuruFocus.comInsider Sale: EVP Strategy and Corporate Development Matthew Dolan Sells Shares of DexCom Inc (DXCM)
Matthew Dolan, Executive Vice President of Strategy and Corporate Development at DexCom Inc (NASDAQ:DXCM), sold 2,423 shares of the company on May 15, 2024.
